RecruitingInterventional · Phase 3NCT03907046 ↗Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and RecoveryMaryna SkliutPIHooman KamelPI
Active, not recruitingInterventional · Phase 3NCT03907488 ↗A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin LymphomaJia RuanPIInterventionProcedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Biological: Filgrastim · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Biological: Pegfilgrastim · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Vinblastine SulfateDatesAug 2019 – Mar 2024· Results postedSponsorSouthwest Oncology GroupAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma+7 more
Active, not recruitingInterventional · Phase 3NCT03914612 ↗A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial CancerEvelyn CantilloPIInterventionDrug: Carboplatin · Procedure: Computed Tomography · Drug: Paclitaxel · Biological: Pembrolizumab · Other: Placebo Administration · Other: Quality-of-Life Assessment · Other: Questionnaire AdministrationDatesAug 2019 – Dec 2022· Results postedSponsorNRG OncologyEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid Adenocarcinoma+13 more
Active, not recruitingInterventional · Phase 3NCT03914625 ↗A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)Alexander Ja-Ho ChouPIInterventionDrug: Asparaginase Erwinia chrysanthemi · Biological: Blinatumomab · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Dexamethasone · Drug: Doxorubicin Hydrochloride · Drug: Leucovorin Calcium · Drug: Mercaptopurine · Drug: Mercaptopurine Oral Suspension · Drug: Methotrexate · Drug: Pegaspargase · Drug: Prednisolone · Drug: Prednisone · Radiation: Radiation Therapy · Drug: Thioguanine · Drug: Vincristine SulfateDatesJul 2019 – Sep 2027 (est.)SponsorChildren's Oncology GroupB Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaDown Syndrome
RecruitingInterventional · Phase 3NCT03936361 ↗STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTSSantosh Bhaskar MurthyPIInterventionDrug: StatinsDatesJun 2020 – Dec 2028 (est.)SponsorBeth Israel Deaconess Medical Center, Inc.Intracerebral Hemorrhage
RecruitingInterventional · Phase 3NCT03959085 ↗A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyJaclyn RosenzweigPIInterventionProcedure: Biospecimen Collection · Biological: Blinatumomab · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Bone Scan · Drug: Calaspargase Pegol · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Daunorubicin Hydrochloride · Drug: Dexamethasone · Drug: Doxorubicin Hydrochloride · Biological: Inotuzumab Ozogamicin · Drug: Leucovorin Calcium · Procedure: Magnetic Resonance Imaging · Drug: Mercaptopurine · Drug: Methotrexate · Drug: Pegaspargase · Procedure: Positron Emission Tomography · Drug: Prednisolone · Drug: Prednisone · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Thioguanine · Drug: Vincristine SulfateDatesOct 2019 – Mar 2032 (est.)SponsorChildren's Oncology GroupB Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaCentral Nervous System Leukemia+2 more
Active, not recruitingInterventional · Phase 2NCT03964727 ↗A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid TumorsAshish SaxenaPIInterventionDrug: Sacituzumab Govitecan-hziyDatesOct 2019 – Jan 2025· Results postedSponsorGilead Sciences, Inc.Metastatic Solid Tumor
Active, not recruitingInterventional · Phase 3NCT03978000 ↗A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection StudyMatthew Smith-RaskaPIInterventionDrug: IBP-9414 · Drug: PlaceboDatesJul 2019 – Jun 2024 (est.)SponsorInfant Bacterial Therapeutics AB (IBT)Necrotizing Enterocolitis
Active, not recruitingInterventional · Not applicableNCT03981445 ↗A Multi-site Multi-Setting Randomized Controlled Trial (RCT) of Integrated HIV Prevention and HCV Care for People Who Inject Drugs (PWID)Czarina Navos BehrendsPIInterventionBehavioral: ARTAS Adapted Patient Navigation · Behavioral: Adherence CounselingDatesNov 2019 – Sep 2026 (est.)SponsorWeill Medical College of Cornell UniversityHIV PreventionHCVOpioid Use+1 more
RecruitingInterventional · Phase 2NCT03990896 ↗Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialMassimo CristofanilliPIInterventionDrug: TalazoparibDatesNov 2021 – Mar 2027 (est.)SponsorThe General Hospital Corporation (dba Massachusetts General Hospital)Breast Cancer
RecruitingInterventional · Phase 4NCT03991169 ↗Pilot Pragmatic Clinical Trial of Oral Iron Therapy in Children With Chronic Kidney DiseaseOleh M. AkchurinPIInterventionDrug: Ferrous SulfateDatesApr 2019 – Dec 2028 (est.)SponsorWeill Medical College of Cornell UniversityChronic Kidney InsufficiencyChronic Kidney Diseases
Active, not recruitingInterventional · Phase 3NCT03992404 ↗Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb TreatmentJoan StillingPIInterventionDrug: NT 201 · Drug: PlaceboDatesSep 2019 – Jun 2025SponsorMerz Pharma GmbH & Co. KGaALower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Active, not recruitingInterventional · Phase 2NCT03994796 ↗Genomically-Guided Treatment Trial in Brain MetastasesRajiv S. MaggePIInterventionDrug: Abemaciclib · Drug: PI3K Inhibitor paxalisib · Drug: Entrectinib · Drug: AdagrasibDatesOct 2019 – Nov 2025· Results postedSponsorAlliance for Clinical Trials in OncologyCDK Gene MutationMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm+4 more
Active, not recruitingInterventional · Phase 3NCT04006210 ↗A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)Harini SarvaPIInterventionCombination product: ND0612 Solution for SC infusion · Combination product: Placebo for SC infusion · Drug: Oral IR-LD/CD · Drug: Placebo for Oral IR-LD/CDDatesSep 2019 – Nov 2022SponsorNeuroderm, Ltd.Parkinson's Disease
Active, not recruitingInterventional · Phase 1NCT04013685 ↗A Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic GraftAlexandra Gomez ArteagaPIInterventionBiological: Orca-TDatesNov 2019 – Apr 2025SponsorOrca BiosystemsAcute Myeloid LeukemiaAcute Lymphoid LeukemiaMyelodysplastic Syndromes+3 more
Active, not recruitingInterventional · Phase 2NCT04021108 ↗Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)Manish A ShahPIInterventionDrug: Nivolumab 240 MGDatesJul 2019 – Jun 2025· Results postedSponsorWeill Medical College of Cornell UniversityGastroesophageal Adenocarcinoma
Active, not recruitingInterventional · Phase 1/2NCT04041310 ↗A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsManish A ShahPIInterventionBiological: GAd-209-FSP low dose · Biological: MVA-209-FSP low dose · Biological: GAd-209-FSP high dose · Biological: MVA-209-FSP high dose · Biological: GAd20-209-FSP, RP2D · Biological: MVA-209-FSP, RP2D · Drug: KEYTRUDA®DatesOct 2019 – Oct 2026 (est.)SponsorNousCom SRLSolid Tumor, Adult
RecruitingInterventional · Phase 3NCT04041479 ↗Efficacy of Biomarker-guided rTMS for Treatment Resistant DepressionConor ListonPIInterventionDevice: Repetitive Transcranial Magnetic StimulationDatesSep 2021 – Apr 2027 (est.)SponsorWeill Medical College of Cornell UniversityTreatment Resistant DepressionMajor Depressive Disorder
Active, not recruitingInterventional · Phase 1NCT04046445 ↗An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal CancerManish A ShahPIInterventionDrug: ATP128 · Drug: BI 754091 · Drug: VSV-GP128DatesJul 2019 – May 2025 (est.)SponsorAMAL TherapeuticsColorectal CancerMSSStage IV Colon Cancer+3 more
Active, not recruitingInterventional · Phase 2NCT04050436 ↗A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell CarcinomaAnna C PavlickPIInterventionDrug: Cemiplimab · Biological: RP1DatesOct 2019 – Sep 2025 (est.)SponsorReplimune Inc.Cutaneous Squamous Cell CarcinomaAdvanced Cutaneous Squamous Cell CarcinomaMetastatic Cutaneous Squamous Cell Carcinoma